Search | Clinical Trials Finder

Conditions: Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions: Molgramostim nebulizer solution, PARI eFlow nebulizer system; Drug · Device
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more

Conditions: Mycobacterium Infections, Nontuberculous
Interventions: Recombinant human interleukin-7; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leprosy
Interventions: clofazamine; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Irvine, California

Conditions: Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous
Interventions: Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline; Biological · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions: Thalidomide; Drug
Lead sponsor: Aaron Diamond AIDS Research Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: New York, New York

Conditions: Post-COVID / Long-COVID
Interventions: Placebo, Sipavibart; Drug · Biological
Lead sponsor: Nancy Klimas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Fort Bragg, North Carolina • Lackland Air Force Base, Texas

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin, Zidovudine, Didanosine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: Immune Modulation, Tuberculosis, Leprosy, Pertussis, Lyme Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Clofazimine, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Interventions: Interleukin-12; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 16 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 13 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more

Conditions: Atypical Mycobacterium Infection
Interventions: Interleukin-12; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 51
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more

Conditions: Cystic Fibrosis
Interventions: Ethambutol, Rifampin, Azithromycin, Pancrelipase; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions: SPR720, Placebo, Open-label Standard of Care; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more

Conditions: Mycobacterium Avium-Intracellulare Infection
Interventions: Cytokine therapy, Interferon Gamma, GM-CSF; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Interleukin-12; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 16
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: Phoenix, Arizona • Harbor City, California • Irvine, California + 17 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Search by objective public record fields.

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

CD8 Reactivity to Microorganisms in Blood and Breast Milk

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection

A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients